Daniel J. Levangie

Mr. Levangie has been a member of Renovia’s Board since June 2018. Mr. Levangie is an experienced executive and corporate director with senior operating experience in the field of medical devices and in vitro diagnostics. He is currently co-founder and Managing Partner of ATON Partners, a private investment firm and Chairman, President & CEO of CereVasc, LLC, an early-stage medical device company. Until January 2017 Mr. Levangie was President of Insulet Drug Delivery Systems following his tenure as Lead Independent Director of Insulet Corporation. From 2011 through 2013 Mr. Levangie served as Chief Executive Officer of Dune Medical Devices while remaining as co-founder and Managing Partner of Constitution Medical Investors, Inc. (CMI) a Boston-based private investment and product development firm acquired by Roche Diagnostics Corporation in July 2013.

Prior to the above, Mr. Levangie held a variety of executive management positions with Cytyc Corporation until the acquisition of Cytyc Corporation by Hologic, Inc. in October of 2007. Those positions included Executive Vice President and Chief Operating Officer, Chief Executive Officer and President of Cytyc Health Corporation, Executive Vice President and Chief Commercial Officer and President, Cytyc Surgical Products Division. Prior to joining Cytyc Corporation in 1992, Mr. Levangie held a number of sales, marketing and management positions with Abbott Laboratories, North Chicago, IL.

Mr. Levangie resides in Boston, MA with his wife Joan, and is a member of the Board of Directors of Exact Sciences, Inc. (Nasdaq: EXAS), Dune Medical Devices and CereVasc, LLC. Mr. Levangie, a graduate of the College of Pharmacy of Northeastern University in Boston, is a member of the Advisory Board of the Barnett Institute of Northeastern University and is a trustee of Excel Charter School, East Boston.